Novo Nordisk (NVO), the maker of popular obesity/diabetes medications Ozempic and Wegovy, warned Thursday that the Trump ...

Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of ...

Over 31 million Americans borrowed a collective $74 billion to pay for healthcare last year, a West Health-Gallup survey ...

As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...

Some lifesaving health projects that had their U.S. funding contracts abruptly terminated last week have received letters ...

U.S. taxpayers spent billions developing Ozempic-type diabetes and weight-loss drugs — now those drugs’ markups could ...

Novo Nordisk (NVO) plans to study how its GLP-1 drugs marketed as Wegovy and Ozempic for obesity and diabetes can help tackle ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Novo Nordisk A/S (NVO) has lowered prices of its blockbuster drug Wegovy for U.S. customers through a new direct-to-consumer online pharmacy, ...

Bloomberg reports the obesity drug market is expected to reach as much as $130 billion in annual sales by 2030.

Novo Nordisk 's ( NVO 3.84%) latest move in the retail sphere was met with approval from market participants Wednesday. They bid the stock up by nearly 4% following the company's news, a performance ...

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients without insurance.